The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

New therapies that promote antitumour immunity have been recently developed. Most of
these immunomodulatory approaches have focused on enhancing T-cell responses, either …

High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability,,–
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …

The state and behaviour of a cell can be influenced by both genetic and environmental
factors. In particular, tumour progression is determined by underlying genetic aberrations …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

The ability of circulating tumor cells (CTCs) to form clusters has been linked to increased
metastatic potential. Yet biological features and vulnerabilities of CTC clusters remain …

Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …

Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops
resistance to chemotherapy. An unresolved question is whether resistance is caused by the …

From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …